Loading organizations...
§ Private Profile · San Diego, CA, USA
Biotechnology company developing small molecule inhibitors for precision medicines in oncology, neurology, and inflammation.
Blacksmith Medicines is a San Diego, California-based biotechnology company that develops small molecule inhibitors targeting metal-dependent enzymes, or metalloenzymes, in human physiology to create precision medicines for cancer, neurodegenerative disorders, immuno-oncology, and inflammatory diseases. Founded in 2017 as a spin-out of Forge Therapeutics by CEO Zachary Zimmerman, scientific co-founder Seth Cohen, and COO David Puerta, the enterprise operates with a workforce of ten to fifty employees. The firm sustains its innovative research through venture capital rounds, licensing agreements, joint development projects, milestone payments, and royalties. After securing its initial seed funding in January 2021, the company established strategic collaborations with prominent pharmaceutical and investment partners, including Eli Lilly & Company, Evotec A.G., MP Healthcare Partners, MagnaSci Ventures, and Alexandria Venture Investments. Furthermore, the organization's FG-2101 program is supported by an official NIAID contract.
Blacksmith Medicines has raised $3.3M across 1 funding round.
Blacksmith Medicines has raised $3.3M in total across 1 funding round.
Blacksmith Medicines has raised $3.3M across 1 funding round. Most recently, it raised $3.3M Other Equity in February 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 21, 2024 | $3.3M Venture Round | National Institute OF Allergy And Infectious Diseases | — | Announced |
Blacksmith Medicines has raised $3.3M in total across 1 funding round.
Blacksmith Medicines's investors include National Institute of Allergy and Infectious Diseases.